Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs?

World Journal of Gastroenterology

Volumn 12, Issue 31, 2006, Pages 5078-5080

  Verge, Carmen ^a   Lucena, M Isabel ^a,e   López Torres, Enrique ^a   Puche García, M José ^a   Fraga, Enrique ^b   Romero Gomez, Manuel ^c   Andrade, Raúl J ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e UNIVERSIDAD DE MÁLAGA   (Spain)

Author keywords

Calcium carbimide; Disulfiram; Hepatotoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPRAZOLAM; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM CARBIMIDE; DISULFIRAM; PHENYTOIN; VENLAFAXINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN DIALYSIS; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACTERIAL PERITONITIS; CASE REPORT; CHOLESTASIS; DEATH; DEPRESSION; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FEMALE; HEPATOBILIARY DISEASE; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER TOXICITY; MALE; PRURITUS; URINE COLOR;

EID: 33748313396     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i31.5078     Document Type: Article

References (10)

1. Peachey JE, Brien JF, Roach CA, Loomis CW. A comparative review of the pharmacological and toxicological properties of disulfiram and calcium carbimide. J Clin Psychopharmacol 1981; 1:21-26
2. Moreno A, Vazquez JJ, Ruizdel Arbol L, Guillen FJ, Colina F. Structural hepatic changes associated with cyanamide treatment: cholangiolar proliferation, fibrosis and cirrhosis. Liver 1984; 4:15-21
3. Mason NA. Disulfiram-induced hepatitis: case report and review of the literature. DICP 1989; 23:872-875
4. Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 2006; 44: 791-797
5. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, Gonzalez-Grande R, Pizarro A, Duran JA, Jimenez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmeron J, Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521
6. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123-130
7. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276
8. Bruguera M, Pares A, Heredia D, Rodes J. Cyanamide hepatotoxicity. Incidence and clinico-pathological features. Liver 1987; 7:216-222
9. Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated hepatitis. Ann Intern Med 1999; 130: 944
10. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. Am J Health Syst Pharm 2004; 61: 2272-2279